Effect of Probiotics on Cardiometabolic Health
An Interventional Study for the Beneficial Effects of Probiotics on Cardio-metabolic Health in Chinese Subjects
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Atherosclerosis is a major risk factor for cardiovascular diseases. Recently, dysbiosis of gut microbiota has been reported to play an important role in the pathogenesis of atherosclerosis. Animal studies have demonstrated that administration of probiotics help delay the progression of atherosclerosis through several mechanisms such as reduction in endotoxemia, and enhanced production of short-chain fatty acids.
However, whether administration of probiotics also has a protective effect in subjects with metabolic syndrome (MetS), who are at high risk for developing atherosclerosis, remain unknown.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510080
- Sun Yat-sen University
-
Guangzhou, Guangdong, Kina, 510080
- Department of Nutrition and Food Hygiene
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Local residents aged between 30-60 years old;
- Stable weight (<5% weight change over last 3 months);
- Central obesity defined as waist circumference ≥90 cm in males or ≥80 cm in females, Plus any two of the following four conditions i) Elevated triglycerides: serum triglycerides ≥150 mg/dL (1.7 mmol/L); ii) Reduced HDL cholesterol: serum HDL-c <40 mg/dL (1.03 mmol/L) in males or <50 mg/dL (1.29 mmol/L) in females; iii) Elevated blood pressure: systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg; iv) Elevated fasting plasma glucose: fasting plasma glucose ≥100 mg/dL (5.6 mmol/L)
- Absence of any systemic, cardiovascular diseases, as well as infections within the previous month;
- Absence of any diet or medication that might interfere with metabolic homoeostasis and gut microbiota, especially antibiotics and probiotics 4 weeks before recruitment.
Exclusion Criteria:
- Acute illness or current evidence of acute or chronic inflammatory of infective diseases;
- Participation in regular diet program more than 2 times per week in the latest 3 months prior to recruitment;
- Mental illness rendering them unable to understand the nature, scope, and possible consequences of the study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Probiotics
Subjects are instructed to take one capsule of probiotics daily for a total of 3 months
|
During the study period, subjects are instructed to take one capsule of probiotics daily for a total of 3 months.
Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.
|
|
Placebo komparator: Placebo Control
Subjects are instructed to take one capsule of placebo daily for a total of 3 months
|
During the study period, subjects are instructed to take one capsule of placebo control daily for a total of 3 months.
Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Flow-mediated slowing (FMS)
Tidsramme: from baseline to 12 weeks after intervention
|
FMS is a simple test for endothelial functions measured by Vicorder.
In patients whose endothelial function or flow-mediated vasodilation are compromised, the FMS is substantially reduced.
|
from baseline to 12 weeks after intervention
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
gut microbiota
Tidsramme: from baseline to 12 weeks after intervention
|
Alterations of the composition of gut microbiota evaluated by metagenomics
|
from baseline to 12 weeks after intervention
|
|
microbial metabolites
Tidsramme: from baseline to 12 weeks after intervention
|
alterations of microbial metabolites evaluated by High performance liquid chromatography-mass spectrometry
|
from baseline to 12 weeks after intervention
|
|
Metabolic Syndrome Severity Z Score (MetZ score)
Tidsramme: from baseline to 12 weeks after intervention
|
MetZ score is an weighted score of the five traditional components of Metabolic syndrome (waist, triglyceride, HDL cholesterol, SBP and fasting glucose).
It's used to evaluate the severity of metabolic disorder, and a higher score indicates a more severe status.
|
from baseline to 12 weeks after intervention
|
|
Lipid profiles
Tidsramme: from baseline to 12 weeks after intervention
|
alterations of blood lipids including total cholesterol, triglyceride, LDL cholesterol and HDL cholesterol determined by automatic biochemical analyser
|
from baseline to 12 weeks after intervention
|
|
Blood pressure
Tidsramme: from baseline to 12 weeks after intervention
|
alterations of blood pressure
|
from baseline to 12 weeks after intervention
|
|
Insulin sensitivity
Tidsramme: from baseline to 12 weeks after intervention
|
alterations of HOMA-IR index
|
from baseline to 12 weeks after intervention
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- Pro-2021
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Kardiometabolske risikofaktorer
-
NCT07282418RekrutteringCardiometabolic sundhedsindikatorer
-
NCT07006636Ikke rekrutterer endnuCardiometabolic sundhedsindikatorer | Antioxidantkapacitet i hele kroppen
-
NCT07247487RekrutteringErnæring | Kardiovaskulær (CV) risiko | Cardiometabolic sundhedsindikatorer
-
NCT07044375Tilmelding efter invitationFysisk aktivitet | Selveffektivitet | Kardiometabolske risikofaktorer | Cardiometabolic sundhedsindikatorer
-
NCT07395921Ikke rekrutterer endnuInflammatorisk | Antioxidantstatus, inflammation | Inflammation biomarkører | Antioxidant evner | Cardiometabolic sundhedsindikatorer
-
NCT02569307AfsluttetPsykose | At Risk Mental State (ARMS)
-
NCT07648446RekrutteringDysbiose | Uddannelse om fodring og sundhedstilstand | Cardiometabolic sundhedsindikatorer | Tarmmotilitet
-
NCT03369730AfsluttetFørste episode psykose (FEP) | At Risk Mental State (ARMS)
Kliniske forsøg med Probiotics
-
NCT07098494AfsluttetEnterocolitis | Hirschsprung sygdom | Hirschsprungs sygdom associeret enterocolitis
-
NCT05734833Trukket tilbage
-
NCT06919913Rekruttering
-
NCT07144475Afsluttet
-
NCT06213428Ikke rekrutterer endnuKvinders sundhed | Hjerneplasticitet
-
NCT06380270AfsluttetTolerabilitet | Sikkerhed
-
NCT06252558RekrutteringFedmekirurgiskandidat
-
NCT06676514Afsluttet
-
NCT05230511RekrutteringRygmarvsskader | Neurogen blære
-
NCT06475183AfsluttetMultipel sclerose | Sund ernæring